Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel

Nicoletta Pedemonte, Davide Boido, Oscar Moran, Michele Giampieri, Mauro Mazzei, Roberto Ravazzolo and Luis J. V. Galietta
Molecular Pharmacology July 2007, 72 (1) 197-207; DOI: https://doi.org/10.1124/mol.107.034702
Nicoletta Pedemonte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davide Boido
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oscar Moran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Giampieri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro Mazzei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Ravazzolo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis J. V. Galietta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mutations occurring in the CFTR gene, encoding for the cystic fibrosis transmembrane conductance regulator chloride channel, cause cystic fibrosis (CF). Mutations belonging to class II, such as ΔPhe508, give rise to a protein with both a defective maturation and altered channel gating. Mutations belonging to class III, such as G551D and G1349D, cause only a gating defect. We have previously identified antihypertensive 1,4-dihydropyridines (DHPs), a class of drugs that block voltage-dependent Ca2+ channels, as effective potentiators of CFTR gating, able to correct the defective activity of CFTR mutants (Mol Pharmacol68:1736-1746, 2005). However, optimization of potency for CFTR versus Ca2+ channels is required to design selective compounds for CFTR pharmacotherapy. In the present study, we have established DHP structure-activity relationship for both CFTR potentiation and Ca2+ channel inhibition using cell-based assays for both types of channels. A panel of 333 felodipine analogs was studied to understand the effect of various substitutions and modifications in the DHP scaffold. Our results show that alkyl substitutions at the para position of the 4-phenyl ring lead to compounds with very low activity on Ca2+ channels and strong effect as potentiators on the ΔPhe508, G551D, and G1349D CFTR mutants.

Footnotes

  • This work was supported by grants from the Cystic Fibrosis Foundation Therapeutics, Telethon-Italy (GGP05103), CIPE-Regione Liguria (Biofarma 2), and Fondazione Italiana per la Ricerca sulla Fibrosi Cistica.

  • ABBREVIATIONS: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; NBD, nucleotide-binding domain; DHP, 1,4-dihydropyridine; VDCC, voltage-dependent Ca2+ channel; FRT, Fischer rat thyroid; YFP, yellow fluorescent protein; BayK-8644, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-[trifluoromethyl]phenyl)-3-pyridine carboxylic acid methyl ester.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received February 1, 2007.
    • Accepted April 23, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 72 (1)
Molecular Pharmacology
Vol. 72, Issue 1
1 Jul 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel

Nicoletta Pedemonte, Davide Boido, Oscar Moran, Michele Giampieri, Mauro Mazzei, Roberto Ravazzolo and Luis J. V. Galietta
Molecular Pharmacology July 1, 2007, 72 (1) 197-207; DOI: https://doi.org/10.1124/mol.107.034702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel

Nicoletta Pedemonte, Davide Boido, Oscar Moran, Michele Giampieri, Mauro Mazzei, Roberto Ravazzolo and Luis J. V. Galietta
Molecular Pharmacology July 1, 2007, 72 (1) 197-207; DOI: https://doi.org/10.1124/mol.107.034702
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
  • Characterization of GRD and LCCH3 from Human Louse
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics